Literature DB >> 8032342

Molecular biology of AMP deaminase deficiency.

M Gross1.   

Abstract

In man, there are at least four isoforms of adenosine monophosphate deaminase (AMPD): myoadenylate deaminase in skeletal muscle, the L isoform in liver, and the E1 and E2 isoforms in erythrocytes. Myoadenylate deaminase is encoded by the AMPD1 gene located on chromosome 1 p13-p21, the L isoform by the AMPD2 gene, and both isoforms in erythrocytes by the AMPD3 gene. Myoadenylate deaminase deficiency is found in 2-3% of all muscle biopsies. The inborn type of myoadenylate deaminase deficiency is caused by a single mutant allele harbouring two mutations: C34-->T (Gln-->Stop) and C143-->T (Pro-48-->Leu). Population studies revealed a frequency of the mutant allele of 0.12 in Caucasian Americans and Germans. The C34-->T mutation is located in exon 2, which is alternatively spliced in part of the AMPD1 transcript in human muscle. Since the second mutation does not affect enzyme function, alternatively spliced mRNA encodes a catalytically active enzyme. Only one patient with a disorder linked to liver AMPD has been described so far. In this patient the decreased inhibition of this enzyme by GTP resulted in uric acid overproduction and gout. A complete lack of erythroyte AMPD activity is found in asymptomatic subjects. The molecular basis of both disorders is not yet known.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032342     DOI: 10.1007/bf01880656

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  53 in total

1.  Evidence for sequential expression of multiple AMP deaminase isoforms during skeletal muscle development.

Authors:  R Marquetant; N M Desai; R L Sabina; E W Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

2.  Muscle adenylic acid deaminase activity. Selective decrease in early-onset Duchenne muscular dystrophy.

Authors:  N C Kar; C M Pearson
Journal:  Neurology       Date:  1973-05       Impact factor: 9.910

3.  A novel pathway for alternative splicing: identification of an RNA intermediate that generates an alternative 5' splice donor site not present in the primary transcript of AMPD1.

Authors:  I Mineo; P R Clarke; R L Sabina; E W Holmes
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

4.  Enzyme defect in primary gout.

Authors:  H G Hers; G Van Den Berghe
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321

5.  Distribution of AMP deaminase isozymes in various human blood cells.

Authors:  N Ogasawara; H Goto; Y Yamada; T Watanabe
Journal:  Int J Biochem       Date:  1984

6.  Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect.

Authors:  H Morisaki; T Morisaki; L K Newby; E W Holmes
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

7.  Ergometer exercise in myoadenylate deaminase deficient patients.

Authors:  M Gross; U Gresser
Journal:  Clin Investig       Date:  1993-06

8.  AMP deaminase activity of skeletal muscle in neuromuscular disorders in childhood. Histochemical and biochemical studies.

Authors:  H Nagao; S Habara; T Morimoto; N Sano; M Takahashi; K Kida; H Matsuda
Journal:  Neuropediatrics       Date:  1986-11       Impact factor: 1.947

9.  Ribose administration during exercise: effects on substrates and products of energy metabolism in healthy subjects and a patient with myoadenylate deaminase deficiency.

Authors:  M Gross; B Kormann; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-02-26

10.  AMP deamination and IMP reamination in working skeletal muscle.

Authors:  R A Meyer; R L Terjung
Journal:  Am J Physiol       Date:  1980-07
View more
  6 in total

1.  Structure of Arabidopsis thaliana N6-methyl-AMP deaminase ADAL with bound GMP and IMP and implications for N6-methyl-AMP recognition and processing.

Authors:  Baixing Wu; Dong Zhang; Hongbo Nie; Senlin Shen; Yan Li; Sisi Li
Journal:  RNA Biol       Date:  2019-07-18       Impact factor: 4.652

2.  Phylogenetic analysis reveals a novel protein family closely related to adenosine deaminase.

Authors:  Stephanie A Maier; Julia R Galellis; Heather E McDermid
Journal:  J Mol Evol       Date:  2005-10-20       Impact factor: 3.973

3.  A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice.

Authors:  Joan Helmering; Todd Juan; Chi Ming Li; Mark Chhoa; Will Baron; Tibor Gyuris; William G Richards; James R Turk; Jeff Lawrence; Patrick A Cosgrove; Jim Busby; Ki Won Kim; Stephen A Kaufman; Connie Cummings; George Carlson; Murielle M Véniant; David J Lloyd
Journal:  Lipids Health Dis       Date:  2014-10-31       Impact factor: 3.876

4.  Ovarian cancer detection by DNA methylation in cervical scrapings.

Authors:  Tzu-I Wu; Rui-Lan Huang; Po-Hsuan Su; Shih-Peng Mao; Chen-Hsuan Wu; Hung-Cheng Lai
Journal:  Clin Epigenetics       Date:  2019-11-27       Impact factor: 6.551

5.  AMPD1 C34T Polymorphism (rs17602729) Is Not Associated with Post-Exercise Changes of Body Weight, Body Composition, and Biochemical Parameters in Caucasian Females.

Authors:  Agata Leońska-Duniec; Ewelina Maculewicz; Kinga Humińska-Lisowska; Agnieszka Maciejewska-Skrendo; Katarzyna Leźnicka; Paweł Cięszczyk; Marek Sawczuk; Grzegorz Trybek; Michal Wilk; Weronika Lepionka; Krzysztof Ficek
Journal:  Genes (Basel)       Date:  2020-05-16       Impact factor: 4.096

6.  Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver.

Authors:  Miguel A Lanaspa; Christina Cicerchi; Gabriela Garcia; Nanxing Li; Carlos A Roncal-Jimenez; Christopher J Rivard; Brandi Hunter; Ana Andrés-Hernando; Takuji Ishimoto; Laura G Sánchez-Lozada; Jeffrey Thomas; Robert S Hodges; Colin T Mant; Richard J Johnson
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.